Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits.
The antimitotic, anticancer drug ICRF 159 [(plus or minus)-1,2,'bis(3,5'dioxopiperazine-l-yl)propane] when given to pregnant BALB/c mice, Sprague-Dawley and Wistar rats, and New Zealand white rabbits had mainly embryolethal effects; the margin between no apparent activity and total embryolethality was narrow. A small percentage of fetuses were malformed and some exhibited retarded development. In all three species the time of maximum sensitivity to the drug was early in gestation, between days 6-10 in mice, 6-8 in rats, and 7-10 in rabbits.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000187:drug effects; D005865:Gestational Age; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects*; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D011929:Razoxane / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010879:Piperazines; D011929:Razoxane